Pacira BioSciences announced a strategic collaboration with Johnson & Johnson MedTech to significantly expand the market reach of ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), leveraging its specialized early intervention sales force to co-promote the treatment to existing and new customers. ZILRETTA is Pacira’s extended-release treatment for osteoarthritis knee pain. This agreement is expected to significantly expand access and extend reach across a large portion of the seven million intra-articular knee injections administered to patients annually in the U.S.
“This partnership embodies our 5x30 strategy of leveraging innovative, targeted collaborations that drive growth, enhance our commercial presence, and improve the patient journey with safe, effective non-opioid treatments," said Frank D. Lee, chief executive officer of Pacira BioSciences. “With its proven long-lasting benefits and distinct mechanism of action, ZILRETTA is uniquely positioned to meet a critical need in osteoarthritis pain management, and we believe this agreement will allow us to reach even more patients across the country,” added Mr. Lee.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!